It can't possibly cost this much to manufacture the drug.

Ga-68 PSMA-11 is a radioactive diagnostic agent that targets PSMA, a protein commonly expressed in prostate cancer. The approval expands RadioMedix’s precision nuclear medicine portfolio and supports ...

Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver hormone therapy, according to the results of a large clinical trial led by UCL ...

By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results were encouraging.

A randomized phase III trial run out of the United Kingdom has found that estradiol skin patches suppress testosterone as effectively as standard hormone injections in men with locally advanced or ...

Please provide your email address to receive an email when new articles are posted on . Pylarify TruVu is a new formulation of piflufolastat F 18 injection, which originally earned FDA approval in ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due to its slow growing nature and reduced symptoms. Increased risk factors ...

A novel theranostic approach that targets RET—a newly identified biomarker for neuroendocrine prostate cancer—enables ...

Early-stage trials of a new drug for advanced prostate cancer have yielded "remarkable" results, according to medical experts. This innovative treatment, an immunotherapy designed to harness the ...

Less is more in the case of this cancer treatment. The most common form of cancer among men in the US, after skin cancer, prostate cancer often comes with traditional treatments that cause difficult ...

For the first time ever, NTNU researchers have identified new characteristics of aggressive prostate cancer. The research lays a foundation for the possibility that aggressive prostate cancer can ...